Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Catalyst Pharmaceuticals Inc
CPRX | US
27.37
USD-0.31
-1.12%
CPRX | US
Loading StockChartView...
About Catalyst Pharmaceuticals Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
24/04/2026
Close
27.37
Open
27.65
High
28.10
Low
26.50
Catalyst Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on developing and commercializing therapies for people with rare debilitating chronic neuromuscular and neurological diseases in the United States. It offers Firdapse an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals Inc. was founded in 2002 and is based in Coral Gables Florida.
View LessCPRX | US
Risk
36.5
Sharpe
0.40
Luna's Score
67/100
Recommendation
Buy
Luna says (CPRX | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
Midcap (2B - 10B USD)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
42.2%1 month
36.5%3 months
36.2%6 months
33.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
37.93
Fwd. PE
10.44
Price to book
4.14
Debt to equity
0.01
Debt to assets
0.00
Ent. to EBITDA
17.55
Ent. to rev.
4.95
PEG
-
Other Fundamentals
EBITDA
122.45M
MarketCap
3.25B
MarketCap(USD)
3.25B
Div. yield
-
Op. margin
44.21
Erngs. growth
-
Rev. growth
23.20
Ret. on equity
13.85
Short ratio
5.57
Short perc.
6.02
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.41
Range1M
5.05
Range3M
5.90
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.50
Price X volume
52.94M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 17.55 | 24.85 | Cheaper |
| Ent. to Revenue | 4.95 | 361.91 | Cheaper |
| PE Ratio | 37.93 | 30.05 | Expensive |
| Price to Book | 4.14 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 36.16 | 65.24 | Lower Risk |
| Debt to Equity | 0.01 | -1.88 | Expensive |
| Debt to Assets | 0.00 | 0.48 | Cheaper |
| Market Cap | 3.25B | 3.71B | Par |
